image
Relmada Therapeutics, Inc. RLMD
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 0.6149
-3.04 %
$ 20.4 M
Market Cap
-0.23
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one RLMD stock under the worst case scenario is HIDDEN Compared to the current market price of 0.615 USD, Relmada Therapeutics, Inc. is HIDDEN

RLMD Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one RLMD stock under the base case scenario is HIDDEN Compared to the current market price of 0.615 USD, Relmada Therapeutics, Inc. is HIDDEN

RLMD Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one RLMD stock under the best case scenario is HIDDEN Compared to the current market price of 0.615 USD, Relmada Therapeutics, Inc. is HIDDEN

RLMD Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart RLMD

image
1M 4%
6M 64%
1Y -64%
3Y -692%
5Y -1168%
All
$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.4$0.3$0.3$0.2$0.2Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-83.9 M OPERATING INCOME
19.10%
Growth Rates
1Year 19.10%
3Years 12.61%
5Years -40.90%
7Years -42.83%
10Years -17.24%
-80 M NET INCOME
19.04%
Growth Rates
1Year 19.04%
3Years 14.00%
5Years -456.35%
7Years -36.71%
10Years -14.42%
-51.8 M OPERATING CASH FLOW
-0.19%
Growth Rates
1Year -0.19%
3Years 17.41%
5Years -432.46%
7Years -36.04%
10Years -12.30%
51.6 M INVESTING CASH FLOW
2.20%
Growth Rates
1Year 2.20%
3Years 43.46%
5Years 264.70%
7Years 228.90%
10Years 116.02%
-40.3 K FINANCING CASH FLOW
59.03%
Growth Rates
1Year 59.03%
3Years -0.01%
5Years -5.71%
7Years -0.09%
10Years -0.03%
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-18.2 M OPERATING INCOME
4.50%
Growth Rates
1Year 19.10%
3Years 12.61%
5Years -40.90%
7Years -42.83%
10Years -17.24%
-17.6 M NET INCOME
5.88%
Growth Rates
1Year 19.04%
3Years 14.00%
5Years -456.35%
7Years -36.71%
10Years -14.42%
-18.1 M OPERATING CASH FLOW
-105.32%
Growth Rates
1Year -0.19%
3Years 17.41%
5Years -432.46%
7Years -36.04%
10Years -12.30%
15.4 M INVESTING CASH FLOW
35.38%
Growth Rates
1Year 2.20%
3Years 43.46%
5Years 264.70%
7Years 228.90%
10Years 116.02%
0 FINANCING CASH FLOW
100.00%
Growth Rates
1Year 59.03%
3Years -0.01%
5Years -5.71%
7Years -0.09%
10Years -0.03%
Balance Sheet Relmada Therapeutics, Inc.
image
Current Assets 45.8 M
Cash & Short-Term Investments 44.9 M
Receivables 0
Other Current Assets 886 K
Non-Current Assets 22 K
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 22 K
98.02 %Total Assets$45.8m
Current Liabilities 10.3 M
Accounts Payable 4.13 M
Short-Term Debt 0
Other Current Liabilities 6.16 M
Non-Current Liabilities 4.47 K
Long-Term Debt 0
Other Non-Current Liabilities 4.47 K
40.12 %59.84 %Total Liabilities$10.3m
EFFICIENCY
Earnings Waterfall Relmada Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 30.2 M
Operating Income -83.9 M
Other Expenses -3.91 M
Net Income -80 M
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)(90m)(90m)000(30m)(84m)4m(80m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
0.00% OPERATING MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
0.00% NET MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-225.15% ROE
-225.15%
Averages
1Year -225.15%
3Years -150.91%
5Years -113.88%
7Years -115.69%
10Years -112.01%
-174.56% ROA
-174.56%
Averages
1Year -174.56%
3Years -126.18%
5Years -97.03%
7Years -95.35%
10Years -121.20%
-236.14% ROIC
-236.14%
Averages
1Year -236.14%
3Years -156.83%
5Years -117.43%
7Years -114.58%
10Years -9.89%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Relmada Therapeutics, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -80 M
Depreciation & Amortization 83.9 M
Capital Expenditures 0
Stock-Based Compensation 30.2 M
Change in Working Capital -1.58 M
Others -2.21 M
Free Cash Flow -51.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Relmada Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for RLMD of $5.67 , with forecasts ranging from a low of $2 to a high of $8 .
RLMD Lowest Price Target Wall Street Target
2 USD 225.26%
RLMD Average Price Target Wall Street Target
5.67 USD 821.56%
RLMD Highest Price Target Wall Street Target
8 USD 1201.02%
Price
Max Price Target
Min Price Target
Average Price Target
887766554433221100Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 5
6. Ownership
Insider Ownership Relmada Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
461 K USD 4
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
643 K USD 4
9-12 MONTHS
7. News
Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 Dr. Lotan's distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada's NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., July 15, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Yair Lotan, MD, a distinguished urologic oncologist, as Chair of Relmada's Clinical Advisory Board (CAB). globenewswire.com - 1 week ago
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors Appointment highlights DIMERx's next phase of growth as it advances non-addictive pain therapeutics with support from the NIH HEAL Initiative Appointment highlights DIMERx's next phase of growth as it advances non-addictive pain therapeutics with support from the NIH HEAL Initiative globenewswire.com - 2 weeks ago
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Raj S. globenewswire.com - 1 month ago
Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2025 Earnings Call May 12, 2025 4:30 PM ET Company Participants Brian Ritchie - Investor Relations Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Yair Lotan - Chief, Urology and Oncology Conference Call Participants Uy Ear - Mizuho Securities Matt Barcus - Jefferies Operator Good afternoon. Welcome to the Relmada Therapeutics First Quarter 2025 Earnings Call. seekingalpha.com - 2 months ago
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) globenewswire.com - 2 months ago
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Monday, May 12, 2025 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2025 and recent business progress. globenewswire.com - 2 months ago
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation* globenewswire.com - 2 months ago
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025 Data to be presented in Clinical Trials in Progress Session on Monday, April 28, 2025 globenewswire.com - 2 months ago
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data April 28 th AUA data presentation to highlight study in patients with high-grade  non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be held on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced it will host a virtual key opinion leader (KOL) event on Monday, April 28, 2025 at 4:30 PM ET. globenewswire.com - 3 months ago
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas. globenewswire.com - 3 months ago
Relmada Therapeutics To Present NDV-01 Data at AUA2025 CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association (AUA2025), taking place from April 26-29th in Las Vegas. globenewswire.com - 3 months ago
Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors, IR Sergio Traversa - CEO Maged Shenouda - CFO Conference Call Participants Uy Ear - Mizuho Securities Andrew Tsai - Jefferies Operator Greetings, and welcome to the Relmada Therapeutics, Incorporated Quarter 4 2024 Financial Results Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 3 months ago
8. Profile Summary

Relmada Therapeutics, Inc. RLMD

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 20.4 M
Dividend Yield 0.00%
Description Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Contact 2222 Ponce de Leon Boulevard, Coral Gables, FL, 33134 https://www.relmada.com
IPO Date June 20, 2014
Employees 17
Officers Dr. Richard M. Mangano Ph.D. Consultant Dr. Andrew Cutler Senior Clinical Development Advisor Dr. Sergio Traversa M.B.A., Pharm.D. Chief Executive Officer & Director Mr. Charles S. Ence CPA, M.B.A. Chief Accounting & Compliance Officer Mr. Maged S. Shenouda M.B.A., R.Ph. Chief Financial Officer Ms. Gina DiGuglielmo Vice President & Head of Clinical Operations Mr. Paul E. Kelly M.B.A. Chief Operating Officer & Director